Abstracts Archive - Page 1838 of 2607 - ACR Meeting Abstracts

Abstract Number: 2763 • 2015 ACR/ARHP Annual Meeting
Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, Shows Similar Pharmacokinetics and Pharmacodynamics Profiles in Japanese and Caucasian Healthy Volunteers
Namour Florence¹, Béatrice Vayssière¹, René Galien², Liesbeth Fagard³, Annegret Van der Aa³, Sandy Goss⁴, Pille Harrison³ and Chantal Tasset³, ¹Galapagos SASU, Romainville, France, ²102 Avenue Gaston Roussel, Galapagos SASU, Romainville, France, ³Galapagos NV, Mechelen, Belgium, ⁴Abbvie, Chicago, IL
Background/Purpose: Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor combining clinical efficacy and a rapid onset of action with a good safety profile…
Abstract Number: 2764 • 2015 ACR/ARHP Annual Meeting
Head-to-Head Comparison of the Retention Rate of First Biologics in Elderly Patients with Rheumatoid Arthritis in Japanese Clinical Practice: Results from the Multicenter Biologic Registry
Masatoshi Hayashi¹, Toshihisa Kanamono², Hiroyuki Matsubara³, Toshihisa Kojima⁴, Koji Funahashi⁵, Nobunori Takahashi⁴ and Naoki Ishiguro⁶, ¹Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Reumatology, Nagano Red Cross Hospital, Nagano, Japan, ³Department of Orthopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ⁴Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁵Nagoya University, Nagoya, Japan, ⁶Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: The objective of this report was to clarify and compare the retention rate of first biologics used to treat elderly Japanese patients with rheumatoid…
Abstract Number: 2765 • 2015 ACR/ARHP Annual Meeting
Long-Term Retention Rate of First Biologics in Patients of Age over 75 Years with Rheumatoid Arthritis in Japanese Clinical Practice: Results from the Multicenter Biologic Registry
Masatoshi Hayashi¹, Toshihisa Kanamono², Hiroyuki Matsubara³, Toshihisa Kojima⁴, Koji Funahashi⁵, Nobunori Takahashi⁴ and Naoki Ishiguro⁶, ¹Department of Orhtopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Reumatology, Nagano Red Cross Hospital, Nagano, Japan, ³Department of Orthopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ⁴Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁵Nagoya University, Nagoya, Japan, ⁶Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: The objective of this report was to clarify and compare the retention rate of first biologics used to treat elderly Japanese patients with rheumatoid…
Abstract Number: 2766 • 2015 ACR/ARHP Annual Meeting
Glucocorticoid-Sparing Effects of Abatacept in Real Life Practice: Data from a Paneuropean Analysis of RA Registries
Jacques Gottenberg¹, Xavier Mariette², Maria Victoria Hernandez³, Florenzo Iannone⁴, Elisabeth Lie⁵, Helena Canhão⁶, Karel Pavelka⁷, Carl Turesson⁸, Merete Lund Hetland⁹ and Axel Finckh¹⁰, ¹Hautepierre, Strasbourg, France, ²Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ³Biobadaser, Barcelona, Spain, ⁴Bari University, Rheumatology, Bari, Italy, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, Lisbonne, Portugal, ⁷Charles University, Prague, Czech Republic, ⁸Lund University, Rheumatology, Dept. of Clinical Sciences,, Malmö, Sweden, ⁹DANBIO, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ¹⁰Rheumatology Division, University Hospital of Geneva, Geneva, Switzerland
Background/Purpose: Despite disease modifying anti-rheumatic drugs (bDMARDs), glucocorticoids (GCs) are still widely prescribed in rheumatoid arthritis (RA). GCs are associated with numerous potential side effects,…
Abstract Number: 2767 • 2015 ACR/ARHP Annual Meeting
Comparative Analysis of Drug Effects on Primary Human Coronary Artery Endothelial Cells Activated By Serum Amyloid a
Katja Lakota¹, Dolores Hrušovar², Katjusa Mrak-Poljšak³, Polona Žigon¹, SaÂša Čučnik^1,2, Borut BoÂžiÄ�^2,3, Matija Tomšič¹ and Snezna Sodin Semrl^1,4, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia, ³University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁴Faculty of Mathematics, Natural Science and Information Technology, University of Primorska, Koper, Slovenia
Background/Purpose: In certain chronic diseases, such as rheumatoid arthritis (RA), atherosclerosis is more prevalent. RA patients have a higher incidence of cardiovascular disease and at…
Abstract Number: 2768 • 2015 ACR/ARHP Annual Meeting
Trend and Factors Associated with Switching Treatment after Initial Anti-TNF Therapy Among Patients with Rheumatoid Arthritis
Wenhui Wei¹, Emma Sullivan², Chieh-I Chen³, James Piercy² and Stuart Blackburn², ¹Sanofi-Aventis, Bridgewater, NJ, ²Adelphi Real World, Manchester, United Kingdom, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Among rheumatoid arthritis (RA) patients who progress beyond their first biologic disease-modifying antirheumatic drug (bDMARD), in-class cycling between different tumor necrosis factor inhibitors (TNFi)…
Abstract Number: 2769 • 2015 ACR/ARHP Annual Meeting
Factors Associated with TNF Switching: a Retrospective Real-World Study of Patients with Rheumatoid Arthritis
Wenhui Wei¹, Keith Knapp², Li Wang³, Chieh-I Chen⁴, Gary Craig², Karen Ferguson² and Sergio Schwartzman⁵, ¹Sanofi-Aventis, Bridgewater, NJ, ²Discus Analytics, Inc., Spokane, WA, ³Director, Analytic Research, STATinMED Research, Plano, TX, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Switching of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patient treatment is common in real-world clinical practice. The context for why patients switch…
Abstract Number: 2770 • 2015 ACR/ARHP Annual Meeting
Efficacy of Sarilumab Plus Methotrexate in Achieving Clinical Remission, Using 4 Different Definitions, in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis in a Phase 3 Study
Mark C. Genovese¹, Marina Stanislav², Hubert van Hoogstraten³, Renata Martincova⁴, Chunpeng Fan⁵ and Janet van Adelsberg⁶, ¹Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Research Institute of Rhumato, Moscow, Russia, ³Sanofi, Bridgewater, NJ, ⁴Sanofi Czech Republic, Prague, Czech Republic, ⁵Biostatistics, Sanofi, Bridgewater, NJ, ⁶Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY
Background/Purpose: Remission is an important clinical outcome in RA1 and is associated with improved physical function and health-related quality of life.2 Several definitions of remission…
Abstract Number: 2771 • 2015 ACR/ARHP Annual Meeting
Impact of Tocilizumab Monotherapy in Patients with Moderate to High Disease Activity: Real-World Analyses from the US Corrona Registry
Leslie Harrold^1,2, Ani John³, George W. Reed^1,4, Chitra Karki¹, YouFu Li⁴, Joel Kremer⁵, Tmirah Haselkorn⁶ and Jeffrey D. Greenberg^1,7, ¹Corrona, LLC, Southborough, MA, ²Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, ³Genentech, Inc., South San Francisco, CA, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY
Background/Purpose: Little is known regarding the real-world use and effectiveness of the interleukin-6 receptor α inhibitor tocilizumab (TCZ) as monotherapy. The effectiveness of TCZ monotherapy…
Abstract Number: 2772 • 2015 ACR/ARHP Annual Meeting
Activated Memory B Cells in Rheumatoid Arthritis and Relationship to Anti-TNF Treatment
Jennifer Barnard¹, Nida Meednu², Kelly Callahan¹, Andreea Coca¹, Bethany A. Marston¹, Ralf G. Thiele¹, Darren Tabechian¹, Marcy Bolster³, Jeffrey R. Curtis⁴, Meggan C. Mackay⁵, Jonathan D. Graf⁶, Richard Keating⁷, Edwin Smith⁸, Karen Boyle⁹, Lynette Keyes-Elstein⁹, Beverly Welch¹⁰, Ellen Goldmuntz¹¹ and Jennifer H. Anolik¹, ¹University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³MUSC, Charleston, SC, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Autoimmune & Musculoskeletal Disorders, The Feinstein Institute for Medical Research, Manhasset, NY, ⁶Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ⁷University of Chicago, Chicago, IL, ⁸Dept of Med Div of Rheum, MUSC, Charleston, SC, ⁹Rho Federal Systems, Inc., Chapel Hill, NC, ¹⁰6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ¹¹DAIT, NIAID/NIH, Bethesda, MD
Background/Purpose: TNF blockade is a mainstay of treatment for rheumatoid arthritis (RA), but a significant proportion of patients fail to respond to treatment or lose…
Abstract Number: 2773 • 2015 ACR/ARHP Annual Meeting
Novel Mechanisms of Action for Methotrexate and Doxycycline: Prevention of Protein Adduct Formation and Free Radical Scavenging
Daniel Anderson¹, Michael J. Duryee², Matthew Zimmerman³, Jun Tian³, Cleofes Sarmiento³, Lynell W. Klassen⁴, James R. O'Dell¹, Geoffrey M. Thiele⁵ and Ted R. Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Cell Biology and Physiology, University of Nebraska Medical Center, Omaha, NE, ⁴Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Oxidative stress and free radical formation play an important pathogenic role in rheumatoid arthritis (RA) and a number of other inflammatory diseases. Oxidative stress…
Abstract Number: 2774 • 2015 ACR/ARHP Annual Meeting
Longterm Outcome of Patients Switched from Iv to Sc Formulation of Abatacept: A Monocentric Study
Rossella Reggia¹, Ilaria Cavazzana¹, Angela Tincani² and Franco Franceschini¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: Abatacept is a selective T cell costimulation modulator indicated for active Rheumatoid Arthritis (RA). Since August 2013, in Italy, the drug has also been…
Abstract Number: 2775 • 2015 ACR/ARHP Annual Meeting
What Factors Are Associated with Starting an Intravenous Vs. Sub-Cutaneous Biologic in Patients with RA?
Kaleb Michaud^1,2, Sofia Pedro² and Steven Peterson³, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To characterize which factors are associated with RA patients' preferences for biologic administration: sub-cutaneous or intravenous.Methods: Using a large US observational cohort, the National…
Abstract Number: 2776 • 2015 ACR/ARHP Annual Meeting
Profiling Compounds in Human Primary Cell-Based Disease Models Guide Indication Selection
Jason Ptacek, Ellen L. Berg and Alison O'Mahony, BioSeek, a division of DiscoveRx Corp., South San Francisco, CA
Background/Purpose: In vitro co-cultures of human primary cells, including immune cells, fibroblasts, smooth muscle, keratinocytes, epithelial or endothelial cells were developed to capture the complexity…
Abstract Number: 2777 • 2015 ACR/ARHP Annual Meeting
Drug Retention Rates of Biologic Monotherapies for Patients with Rheumatoid Arthritis Receiving TNF Inhibiting Fusion Protein Agent and Antibody Agent; From Multicenter Registry in Japan
Hiroyuki Matsubara¹, Masatoshi Hayashi², Nobunori Takahashi³, Toshihisa Kojima³, Koji Funahashi³ and Naoki Ishiguro⁴, ¹Department of Orthopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ²Department of Orhtopedic Surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ³Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: In general, drug retention rate reflects the effectiveness and tolerability of the drug. TNF inhibitors include fusion protein agent such as etanercept (ETN) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].